<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="585">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02559349</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 15415</org_study_id>
    <nct_id>NCT02559349</nct_id>
  </id_info>
  <brief_title>Gut Microbiota And Radiotherapy</brief_title>
  <official_title>Gut Microbiota And Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pilot, single arm, single center study to determine the feasibility of obtaining stool
      samples from adult patients receiving SBRT to a lung tumor, if SBRT induces changes in the
      gut microbiota and to obtain preliminary data about possible correlation of baseline
      composition and changes in gut microbiota with tumor response, local control, and
      development of pneumonitis/other side effects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Number of subject providing stool samples</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Lung Tumor</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stool Collection</intervention_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Stool Sample
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients receiving SBRT to a lung tumor
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is planned to receive Stereotactic Body Radiotherapy (SBRT) to a lung lesion
             (either presumed or biopsy-proven NSCLC

          -  Age 18 years old or older

          -  Patient capable of giving informed consent

        Exclusion Criteria

          -  Use of antibiotics, antifungal, antivirals or antiparasitics during the 4 weeks prior
             to registration

          -  Active infection with oral temperature &gt;100Â°F

          -  Use of corticosteroids, methotrexate or immunosuppressive drugs during the 4 weeks
             prior to registration

          -  Use of chemotherapy during the 4 weeks prior to radiotherapy or during radiotherapy.
             Chemotherapy cannot begin before the collection of the 30-day post treatment sample
             (S4).

          -  Confirmed or suspected HIV, HBV or HCV

          -  Chronic constipation (bowel movements less frequent than every other day)

          -  Active uncontrolled gastrointestinal disorders such as inflammatory bowel disease,
             moderate/severe irritable bowel syndrome, persistent, infectious gastroenteritis,
             colitis or gastritis, persistent or chronic diarrhea of unknown etiology, Clostridium
             Difficile infection (recurrent) or Helicobacter Pylori infection (untreated)

          -  Major surgery of the GI tract, with the exception of cholecystectomy and
             appendectomy, in the past five years. Any major bowel resection at any time

          -  Patients on anti-diarrheal medications

          -  Patients on probiotics
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edgar Ben-Josef, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Edgar Ben-Josef, MD</last_name>
    <phone>855-216-0098</phone>
    <email>PennCancerTrials@emergingmed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edgar Ben-Josef, MD</last_name>
      <phone>855-216-0098</phone>
      <email>PennCancerTrials@emergingmed.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 11, 2016</lastchanged_date>
  <firstreceived_date>September 22, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stereotactic Body Radiotherapy</keyword>
  <keyword>SBRT</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
